Single blind study to assess the efficacy and tolerance of BF 2.649 in adults suffering from Attention Deficit/Hyperactivity Disorder

BIOPROJET0 个研究点目标入组 20 人开始时间: 2005年11月24日最近更新: 2014年10月7日

试验速览

暂无简介。

•- Male or Female aged from 18 to 65 years old
•- Ambulatory patients suffering from Attention Deficit / Hyperactivity Disorder (according to DSM-IV criteria)
•- No specific medications for ADHD treatment
•- Score superior to 46 on WURS scale
•- Informed written consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Psychiatric disorders:
•- All psychiatric diseases other than ADHD
•Psychotropic medications:
•- Any prescription of Atomoxetine, anti-depressants, anti-psychotics, mood stabilizers during the previous 4 weeks,
•- Any psychostimulants (methylphenidate), benzodiazepine, zolpidem, zopiclone, zaleplon and any medication with psychic effects in the past 2 weeks.
•- Severe systemic illnesses and any illness, which according to the investigator's judgement, will expose the patient to an excessive risk
•- ECG: auriculo-ventricular block with PR > 200 MS and/or QTc > 450 ms
•- Biological tests: values considered to be abnormal by the investigator

发起方